About ImmPACT-Bio
ImmPACT-Bio is a company based in Ness Ziona (Israel) founded in 2017, and was acquired by Lyell Immunopharma in October 2024. Biotechnology research and development are conducted in Israel. ImmPACT-Bio has raised $157.86 million across 3 funding rounds from investors including Lyell Immunopharma, Orbimed and Bukwang Pharmaceutical. Its chief executive, as recorded, is Merav Beiman. ImmPACT-Bio offers products and services including Bispecific CAR T Cells and TGF-Ξ² CAR. Its legal entity is ImmPACT Bio, Inc.
Company details
ImmPACT-Bio was founded in 2017 and is based in Ness Ziona, Israel. Operations in the biotechnology sector are centered on the advancement of biological products and therapies. Research efforts are led by CEO Merav Beiman, with a focus on innovative medical solutions. Activities are conducted primarily in Israel, addressing needs in biopharmaceutical applications across various therapeutic areas. Limited details on specific services are available.
- Headquarters Ness Ziona, Israel
- Stage Acquired
- Website immpact-bio.com
- Social LinkedIn
- Acquired by Lyell Immunopharma (Oct 2024)
- Legal Name Immpact Bio, Inc
- Total Equity Funding$157.86M (USD)
in 3 rounds
- Latest Funding Round$8M (USD), Grant
Feb 2024
- InvestorsLyell Immunopharma
& 13 more
- Acquired byLyell Immunopharma
(Oct 2024)
Products & Services of ImmPACT-Bio
ImmPACT-Bio offers a comprehensive portfolio of products and services, including Bispecific CAR T Cells and TGF-β CAR.
Bispecific CAR T cells are employed to prevent antigen escape in cancer and autoimmune diseases
TGF-β CAR is utilized to rewire T cell responses against immunosuppressive microenvironments in cancer
Funding Insights of ImmPACT-Bio
ImmPACT-Bio has successfully raised a total of $157.86M across 3 strategic funding rounds. The most recent funding activity was a Grant round of $8 million completed in February 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $157.86M
- Total Rounds 3
- Last Round Grant β $8M
- First Round $18M
(Aug 2020)
- Investors Count 13
All 3 funding rounds of ImmPACT-Bio with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2024 | $8M | Grant | β | β | β |
| Jan 2022 | $139.86M | Series B | β | VenBio, Foresite Capital | |
| Aug 2020 | $18M | Series A | β | Orbimed, Johnson & Johnson Innovation – JJDC | β |
14 investors in total: 14 institutional.
Investors in ImmPACT-Bio
ImmPACT-Bio has secured backing from 14 investors, including venture fund and institutional investors. Prominent investors backing the company include Lyell Immunopharma, Orbimed and Bukwang Pharmaceutical.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
A life sciences investment firm focused on novel therapeutics is operated. | 2011 | venbio.com | San Francisco, United States | |
Multi-stage investment firm invests in healthcare and life sciences companies | foresitecapital.com | New York, United States | ||
Venture capital firm focused on life science and technology sectors | decheng.com | Shanghai, China | ||
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields. | 1989 | orbimed.com | New York, United States | |
Investments are made in innovative life science companies globally. | nvfund.com | Basel, Switzerland | ||
Venture capital firm backed by Johnson & Johnson | jnjinnovation.com/jjdc | Cambridge, United States | ||
| takedaventures.com | ||||
| hayan.com | ||||
| rmgpfund.com | ||||
Venture capital investment firm | jvcmanagement.com | Northbrook, United States |
Investor details for ImmPACT-Bio
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of ImmPACT-Bio
44 people are tracked at ImmPACT-Bio (15 in leadership, 13 in board & advisors, 16 in team).
| Name | Role | Group |
|---|---|---|
Merav Beiman | CEO | Leadership |
Yang Qiu | Director, MSAT | Leadership |
Jenny Cui | Group Head, Research | Leadership |
Satyakam Singh | Director, Head Of Cell And Gene Therapy Analytical Method Development In Process Sciences | Leadership |
Urszula Abbassi | HR Business Partner | Leadership |
Rahul Patel | Executive Medical Director | Leadership |
Venkata P. Yepuri | COO | Leadership |
Todd Stallings-Schmitt | Head, Clinical Development Operations | Leadership |
Jolie Keough | VP, Human Resources | Leadership |
Orit Foord | Head, Protein Sciences | Leadership |
Shirin Ghavam | Senior Director, Program Management | Leadership |
Jennifer Anuran-Reyes | Executive Director, Head of Quality | Leadership |
Arugadoss Devakumar | Director Of Quality Control | Leadership |
Omar Pugach | Associate Director Quality Assurance | Leadership |
Ramon Montejano | Associate Director, CMC Project Management & Business Coordination | Leadership |
Erez Chimovits | Board Member | Board & advisors |
Saar Gill | Scientific Advisor | Board & advisors |
Sheila Gujrathi | Chairperson | Board & advisors |
Cindy Xiong | Board Member | Board & advisors |
Min Cui | Director | Board & advisors |
24 more people are available in the full profile.
Complete people profiles for ImmPACT-Bio
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of ImmPACT-Bio
4 dated milestones of ImmPACT-Bio across 7 years, from founding to its latest funding, stage changes and deals.
- Founded ImmPACT-Bio is founded.
- Funding First funding round of $18.0M.
- Funding Latest funding round, Grant, of $8.0M.
- Exit Acquired by Lyell Immunopharma.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about ImmPACT-Bio
ImmPACT-Bio was founded in 2017 and raised its 1st funding round 3 years after it was founded.
ImmPACT-Bio is headquartered in Ness Ziona, Israel. It is registered at Ness Ziona, Central District, Israel.
Merav Beiman is the CEO of ImmPACT-Bio, as recorded in our data.
ImmPACT-Bio is a funded company, having raised a total of $157.86M across 3 funding rounds to date. The company's 1st funding round was a Series A of $18M, raised on Aug 2020.
ImmPACT-Bio was founded in 2017 and is based in Ness Ziona, Israel. Operations in the biotechnology sector are centered on the advancement of biological products and therapies. Research efforts are led by CEO Merav Beiman, with a focus on innovative medical solutions. Activities are conducted primarily in Israel, addressing needs in biopharmaceutical applications across various therapeutic areas. Limited details on specific services are available.
ImmPACT-Bio offers Bispecific CAR T Cells and TGF-Ξ² CAR.
ImmPACT-Bio has 14 investors. Key investors include Lyell Immunopharma, Orbimed, Bukwang Pharmaceutical, venBio, and Foresite Capital.
ImmPACT-Bio operates through Immpact Bio, Inc.
Yes. ImmPACT-Bio was acquired by Lyell Immunopharma in October 2024.